A Canadian Working Group Report on Fecal Microbial Therapy: Microbial Ecosystems Therapeutics
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
A working group from across Canada comprised of clinician and basic scientists, epidemiologists, ethicists, Health Canada regulatory authorities and representatives of major funding agencies (Canadian Institutes of Health Research and the Crohn's and Colitis Foundation of Canada) met to review the current experience with fecal microbial therapy and to identify the key areas of study required to move this field forward. The report highlights the promise of fecal microbial therapy and related synthetic stool therapy (together called 'microbial ecosystems therapeutics') for the treatment of Clostridium difficile colitis and, possibly, other disorders. It identifies pressing clinical issues that need to be addressed as well as social, ethical and regulatory barriers to the use of these important therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Health Canada regards FMT as a “New Biologic Drug” and declares that all clinical studies must pass the process of a clinical trial application to ensure it meets quality and safety standards.75”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [75]
In the citing paper
“a YouTube video describing do-it-yourself FMT has been viewed over 45,000 times.112”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887 · cited 1×
“Information from 16S rRNA sequence analysis can be used to characterize the gross composition of the microbiota using tools such as Quantitative Insights Into Microbial Ecology (31).”
MethodCohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma
Castellarin, M., Warren, R. L., Freeman, J. D., Dreolini, L., Krzywinski, M., Strauss, J., Barnes, R., Watson, P., Allen-Vercoe, E., Moore, R. A., et al. (2012) · Genome Research · doi:10.1101/gr.126516.111 · Cited by 2,043 · cited 1×
“For example, if certain bacterial profiles are associated with colorectal cancer (21,22), their transplantation may have future consequences for the recipient.”
BackgroundSelf-citationDiet Drives Convergence in Gut Microbiome Functions Across Mammalian Phylogeny and Within Humans
Muegge, B. D., Kuczynski, J., Knights, D., Clemente, J. C., González, A., Fontana, L., Henrissat, B., Knight, R., & Gordon, J. I. (2011) · Science · doi:10.1126/science.1198719 · Cited by 1,988 · cited 1×
“In some cases, it has been possible to identify specific groups of organisms that are strongly associated with a particular condition (32).”
BackgroundGenomic analysis identifies association of Fusobacterium with colorectal carcinoma
Kostic, A. D., Gevers, D., Pedamallu, C. S., Michaud, M., Duke, F., Earl, A. M., Ojesina, A. I., Jung, J., Bass, A. J., Tabernero, J., et al. (2012) · Genome Research · doi:10.1101/gr.126573.111 · Cited by 1,960 · cited 1×
“For example, if certain bacterial profiles are associated with colorectal cancer (21,22), their transplantation may have future consequences for the recipient.”
BackgroundLoo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Pepin, J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041104 · Cited by 1,128 · cited 1×
“Between 2002 and 2005, a large outbreak of the hypervirulent strain NAP1 in Quebec led to quadrupling of annual CDI incidence compared with baseline rates from 1991 (2,3).”
Clostridium difficile infection in Europe: a hospital-based survey
Bauer, M. P., Notermans, D. W., van Benthem, B. H., Brazier, J. S., Wilcox, M. H., Rupnik, M., Monnet, D. L., van Dissel, J. T., & Kuijper, E. J. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61266-4 · Cited by 1,020 · cited 1×
“Concern has been expressed that food may be a source of exposure (17), and increases in the prevalence of 078 have been reported internationally (18-20).”
BackgroundDecreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010 · cited 2×
“Recurrent CDI is believed to result from the inability of the intestinal microbiota to recover and re-establish itself to homeostasis with the host (we henceforth use the term ‘normal’ to mean one that does not cause symptoms and signs of infection), after an initial insult, such as antimicrobial exposure (7-10).”
BackgroundGough, E., Shaikh, H., & Manges, A. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir632 · Cited by 1,003 · cited 1×
“However, a recent systematic review suggests that administration by NJ tube may be inferior to the rectal route (11).”
Background
Cited by
Hill (2014) · doi:10.1038/nrgastro.2014.66 · Cited by 9,592
Petrof, E. O., Gloor, G. B., Vanner, S. J., Weese, S. J., Carter, D., Daigneault, M. C., Brown, E. M., Schroeter, K., & Allen-Vercoe, E. (2013) · Microbiome · doi:10.1186/2049-2618-1-3 · Cited by 731
“The treatment seems equally effective when the young donors are not related [19,23].”
BackgroundSelf-citationOtt, S. J., Waetzig, G. H., Rehman, A., Moltzau-Anderson, J., Bharti, R., Grasis, J. A., Cassidy, L., Tholey, A., Fickenscher, H., Seegert, D., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.010 · Cited by 695
Fecal microbiota transplantation: Review and update
Wang, J.-W., Kuo, C.-H., Kuo, F.-C., Wang, Y.-K., Hsu, W.-H., Yu, F.-J., Hu, H.-M., Hsu, P.-I., Wang, J.-Y., & Wu, D.-C. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.08.011 · Cited by 576
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., Moore, T., & Wu, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.008 · Cited by 572
“However, Health Canada considers FMT and related synthetic stool therapies as a “New Biologic Drug” and requires any clinical study go through the process of a clinical trial application (CTA) to ensure that quality and safety standards are met.(127) The United States Food and Drug Administration (FDA) has determined…”
Metadata
- Authors
- Allen-Vercoe, E., Reid, G., Viner, N., Gloor, G. B., Hota, S., Kim, P., Lee, C., O’Doherty, K. C., Vanner, S. J., Weese, J. S., & Petrof, E. O.
- Affiliations
- University of Guelph, Guelph, Canada
- Western University (CA)
- Health Canada (CA)
- University of Toronto (CA)
- University of Guelph (CA)
- McMaster University (CA)
- Queen's University (CA)
- Corresponding author
- Petrof, Elaine O
- Venue
- Canadian Journal of Gastroenterology
- Publisher
- Hindawi Limited
- Published
- 2012
- Volume
- 26
- Issue
- 7
- Pages
- 457-462
- ISSN
- 0835-7900 (ISSN-L)
- PMC
- PMC3395448
- OpenAlex
- W41667184
- Cited by
- 81
- References
- 39
- Citations by year
- 2024: 12 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 6 · 2017: 7 · 2016: 11 · 2015: 11 · 2014: 11 · 2013: 11 · 2012: 4
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Canadian Journal of Gastroenterology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Infectious Diseases Society of America
- Canadian Institutes of Health Research (94314)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Keywords
- fecal microbiota transplantation, Clostridium difficile infection, gut microbiota, regulatory challenges, ethical considerations, clinical research priorities, inflammatory bowel disease
- MeSH terms
- Canada, Congresses as Topic, Enterocolitis, Pseudomembranous, Feces, Gastroenterology, Humans, Ecosystem, Computational Biology, Metagenome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Canadian Working Group Report on Fecal Microbial Therapy: Microbial Ecosystems Therapeutics. https://app.cochat.ai/papers/10.1155/2012/213828
- The paper
- Allen-Vercoe, E., Reid, G., Viner, N., Gloor, G. B., Hota, S., Kim, P., Lee, C., O’Doherty, K. C., Vanner, S. J., Weese, J. S., & Petrof, E. O. (2012). A Canadian Working Group Report on Fecal Microbial Therapy: Microbial Ecosystems Therapeutics. Canadian Journal of Gastroenterology. https://doi.org/10.1155/2012/213828
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.